GlassScriptPhysician profile
Ashley Dominique
NPI 1437454634
$4,142.03
in general payments reported to CMS, 2019-2025
24 companies · $568 in 2025
The $568 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $765 · 2022: $745 · 2023: $999 · 2024: $1,066 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Education: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.85 |
| Education | $407.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $877.41 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| Genzyme Corporation | $570.95 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $376.16 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $357.14 | 2021-2025 | |
| Galderma Laboratories, L.P. | $298.19 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $269.79 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $224.85 | 2021-2024 | Taltz, Ebglyss |
| Vyne Pharmaceuticals INC. | $206.28 | 2021 | |
| Pfizer INC. | $124.59 | 2021-2023 | |
| Leo Pharma INC. | $121.13 | 2022-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $113.12 | 2021-2025 | |
| Strata Skin Sciences, INC. | $88.30 | 2024-2025 | Xtrac |
| Amgen INC. | $73.11 | 2022-2024 | Otezla |
| Chiesi USA, INC. | $66.70 | 2024 | Filsuvez |
| Journey Medical Corporation | $59.48 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $53.98 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.31 | 2023 | Spevigo |
| Botanix Sb INC | $47.84 | 2025 | Sofdra |
| Ucb, INC. | $43.21 | 2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $37.84 | 2021 | |
| Sun Pharmaceutical Industries INC. | $30.80 | 2021 | |
| Dermavant Sciences, INC. | $19.19 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $15.24 | 2024 | Sotyktu |
| Organon LLC | $13.42 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Dominique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.